drugset / Trial / NCT04111315

Efficacy of Metamizole Versus Ibuprofen and a Short Educational Intervention Versus Standard Care in Acute Low Back Pain

NCT04111315

Phase 4 Unknown 120 enrolled Insel Gruppe AG, University Hospital Bern
RandomizedFactorialQuadruple-blindTreatment

Summary

The EMISI trial is a randomized, double blind, controlled trial (RCT) using a factorial design in patients with a new low back pain episode. The study aims to assess (A) whether metamizole, a non-opioid drug approved in Switzerland for pain treatment, is non-inferior to ibuprofen in a new episode of acute or subacute LBP and (B) whether a short educational intervention including evidence-based patient information is superior to usual care alone. Despite its increased use, the role of metamizole for the treatment of LBP is unclear and has so far not been systematically studied.

Timeline

Start
2019-12-15
Primary completion
2025-12-30
Completion
2025-12-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ibuprofen Small molecule 600 mg Oral
Comparator Metamizole Unknown 1000 mg Oral

Indications

No indication recorded.